High Court Steps In: Maharashtra FDA Retracts Cipla Drug Licence Cancellation for Pune Facility

In a significant development for the pharmaceutical giant Cipla, the Maharashtra Food and Drug Administration (FDA) has made an unexpected U-turn, withdrawing its recent order that had cancelled the drug sale licence for Cipla’s vital Carry and Forwarding (C&F) facility located at Wadki in Pune. This reversal wasn't just a change of heart; it followed a crucial intervention by the Bombay High Court, essentially pressing the reset button on a rather contentious regulatory action.

You see, the controversy began swirling just a few days prior, in late August 2026, when the FDA had initially directed Cipla to appear for a hearing on August 26. Curiously, that very date happened to be a public holiday. What’s more, the FDA proceeded to pass its cancellation order, effective from August 27, seemingly without the benefit of an actual hearing taking place. This procedural misstep quickly became a focal point of Cipla’s legal challenge.

The grounds for the FDA's initial drastic action were quite serious, centering around alleged irregularities concerning the packaging, storage, and recall processes for specific products, notably ‘Reactin Plus Tablets’. The allegations included some rather thorny issues: unauthorized promotional text found on the packaging of a Schedule H medicine, discrepancies unearthed in stock records, and an alleged non-compliance with recall directions. Such accusations, if proven, could indeed raise eyebrows.

However, Cipla, a company known globally for its pharmaceuticals, wasn't one to take this lying down. They promptly moved the Bombay High Court, arguing vehemently against the FDA’s order. Their legal team, spearheaded by Senior counsel Aabad Ponda, highlighted the procedural lapses, specifically pointing out the absurdity of scheduling a hearing on a public holiday and then issuing a cancellation order without one. Crucially, Cipla also clarified that the FDA’s order did not pertain to the safety, quality, efficacy, or ultimately, the patient safety aspects of their products, which, one might say, is a very important distinction.

The High Court bench, comprising the respected Acting Chief Justice Ravindra Ghuge and Justice Gautam Ankhad, played a pivotal role here. After hearing the arguments from Cipla’s counsel and the Additional government pleader P P Kakade representing the FDA, the court evidently saw merit in Cipla’s petition. It appears the procedural shortcomings were significant enough to warrant a direct intervention.

Ultimately, under the High Court's scrutiny, the Maharashtra FDA chose to withdraw its cancellation order. This means that, for now, Cipla's Pune facility can continue its operations. As part of this new arrangement, the FDA will now issue a fresh show-cause notice to Cipla, allowing the company a proper opportunity to present its case and address the allegations in due course. It's a move that brings the regulatory process back to square one, but this time, with the proper legal steps seemingly being followed.

This outcome underscores the importance of due process in regulatory actions, particularly when dealing with major players in the pharmaceutical industry like Cipla. While the allegations themselves remain to be fully addressed, the court’s intervention ensures that such significant decisions are made with procedural fairness at their core.